Neurofirbromatosis-Pipeline Insight, 2021 | Analytical Research Cognizance

Neurofirbromatosis-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667941
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 60
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “Neurofirbromatosis - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Neurofirbromatosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Neurofirbromatosis Understanding
Neurofirbromatosis: Overview
Neurofibromatosis (NF) is a genetic disorder that causes tumors to develop in the brain, spinal cord, and nerves. The condition occurs as a result of a gene abnormality. There are two types of NF, both of which cause tumor growth in various areas of the body. Neurofibromatosis type 1 (NF1) is more common than neurofibromatosis type 2 (NF2). NF1 causes tumors to form in various tissues and organs of the body. This causes skin problems and bone deformities. NF2, on the other hand, causes tumors to develop on the brain and spinal nerves. Although most tumors caused by NF are not cancerous, they can still be dangerous and impair your quality of life.

"Neurofirbromatosis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neurofirbromatosis pipeline landscape is provided which includes the disease overview and Neurofirbromatosis treatment guidelines. The assessment part of the report embraces, in depth Neurofirbromatosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurofirbromatosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Neurofirbromatosis R&D. The therapies under development are focused on novel approaches to treat/improve Neurofirbromatosis.

Neurofirbromatosis Emerging Drugs Chapters
This segment of the Neurofirbromatosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neurofirbromatosis Emerging Drugs
Mirdametinib: SpringWorks Therapeutics
Mirdametinib is an oral, small molecule MEK inhibitor in development as a monotherapy treatment for neurofibromatosis type 1?associated plexiform neurofibromas, or NF1?PN, and as a combination therapy for the treatment biomarker defined metastatic cancers with mutations in the MAPK pathway, such as in RAS and RAF. Mirdametinib is designed to inhibit MEK1 and MEK2. MEK proteins occupy a pivotal position in the MAPK pathway, which is a key signaling network that regulates cell growth and survival, and that plays a central role in multiple oncology and rare disease indications. The drug is in phase 2 of clinical trials for the treatment of neurofibromatosis.

NFX-179: NFlection Therapeutics
NFlection is developing a topical gel containing NFX-179, a proprietary “soft” (metabolically labile) MEK inhibitor for the reduction of tumor burden of persistently developing cutaneous neurofibromas (cNF) in neurofibromatosis type 1 (NF1). The drug is The drug is in phase 2 of clinical trials for the treatment of neurofibromatosis.
Further product details are provided in the report……..

Neurofirbromatosis: Therapeutic Assessment
This segment of the report provides insights about the different Neurofirbromatosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Neurofirbromatosis
There are approx. 5+ key companies which are developing the therapies for Neurofirbromatosis. The companies which have their Neurofirbromatosis drug candidates in the mid to advanced stage, i.e. phase II include, SpringWorks Therapeutics and others.

Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Late-stage products (phase III)
Mid-stage products (Phase II and Phase I/II)
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Neurofirbromatosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Subcutaneous
Intravenous
Oral
Intramuscular
Molecule Type

Products have been categorized under various Molecule types such as
Small molecules
Natural metabolites
Monoclonal antibodies
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neurofirbromatosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neurofirbromatosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neurofirbromatosis drugs.

Neurofirbromatosis Report Insights
Neurofirbromatosis Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Neurofirbromatosis Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Neurofirbromatosis drugs?
How many Neurofirbromatosis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neurofirbromatosis?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neurofirbromatosis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Neurofirbromatosis and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
SpringWorks Therapeutics
NFlection Therapeutics
CereXis
Nobelpharma
INTiDYN
Merck
Genentech
Array BioPharma

Key Products
Mirdametinib
NFX-179
Rec-2282
NPC-12G
Bevacizumab
Binimetinib

Introduction
Executive Summary
Neurofirbromatosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Neurofirbromatosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Neurofirbromatosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Neurofirbromatosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Mirdametinib: SpringWorks Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Rec-2282: CereXis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Neurofirbromatosis Key Companies
Neurofirbromatosis Key Products
Neurofirbromatosis- Unmet Needs
Neurofirbromatosis- Market Drivers and Barriers
Neurofirbromatosis- Future Perspectives and Conclusion
Neurofirbromatosis Analyst Views
Neurofirbromatosis Key Companies
Appendix

Table 1 Total Products for Neurofirbromatosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Neurofirbromatosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products